DOCSLIB.ORG

Guiding Dengue Vaccine Development Using Knowledge Gained from the Success of the Yellow Fever Vaccine

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Guiding Dengue Vaccine Development Using Knowledge Gained from the Success of the Yellow Fever Vaccine Cellular & Molecular Immunology (2016) 13, 36–46 ß 2015 CSI and USTC. All rights reserved 1672-7681/15 $32.00 www.nature.com/cmi REVIEW Guiding dengue vaccine development using knowledge gained from the success of the yellow fever vaccine Huabin Liang, Min Lee and Xia Jin Flaviviruses comprise approximately 70 closely related RNA viruses. These include several mosquito-borne pathogens, such as yellow fever virus (YFV), dengue virus (DENV), and Japanese encephalitis virus (JEV), which can cause significant human diseases and thus are of great medical importance. Vaccines against both YFV and JEV have been used successfully in humans for decades; however, the development of a DENV vaccine has encountered considerable obstacles. Here, we review the protective immune responses elicited by the vaccine against YFV to provide some insights into the development of a protective DENV vaccine. Cellular & Molecular Immunology (2016) 13, 36–46; doi:10.1038/cmi.2015.76 Keywords: dengue virus; protective immunity; vaccine; yellow fever INTRODUCTION from a viremic patient and is capable of delivering viruses to its Flaviviruses belong to the family Flaviviridae, which includes offspring, thereby amplifying the number of carriers of infec- mosquito-borne pathogens such as yellow fever virus (YFV), tion.6,7 Because international travel has become more frequent, Japanese encephalitis virus (JEV), dengue virus (DENV), and infected vectors can be transported much more easily from an West Nile virus (WNV). Flaviviruses can cause human diseases endemic region to other areas of the world, rendering vector- and thus are considered medically important. According to borne diseases such as dengue fever a global health problem. WHO statistics, approximately 200,000 cases of YF occur The use of vaccines to prevent viral infection is the most cost- annually, leading to 30,000 deaths worldwide.1,2 Although 3 effective public health strategy. Vaccines against YFV (the YF- billion people are at risk of JEV infection, only 20,000 clinical 17D vaccine) and JEV have been effectively used in humans for cases and 6,000 deaths occur annually. However, the case fat- decades. However, a licensed DENV vaccine has not been suc- ality rate of JEV infection ranges from 5 to 30%, and approxi- cessfully developed using similar strategies. Because the DENV mately 30–50% of patients who recover from the infection have vaccine that is in the most advanced stage of clinical develop- permanent neuropsychiatric sequelae, while only one-third of ment is based on a chimera between YF-17D and DENV com- patients have complete remission without lingering complica- ponents, we closely examine the immunological factors that tions.3 Human cases of WNV infection are relatively rare, and have been associated with the protection conferred by the the most recent cases have largely been reported in the USA. YF-17D vaccine in the hopes of elucidating a strategy for the DENV infection has dramatically increased since the Second development of an efficacious DENV vaccine. World War, and 2.5 billion people in more than 100 countries across the tropical and subtropical regions are currently at risk STRUCTURE AND REPLICATION STRATEGY for DENV infection. An estimated 390 million dengue infec- OF FLAVIVIRUSES tions occur every year, of which 96 million manifest clinically as All flaviviruses share similar structural features and replication 4,5 dengue fever. strategies (Figure 1). The mature virion consists of an icosahed- Flaviviruses are transmitted by arthropod vectors, princip- ral particle comprising three structural proteins: the capsid ally represented by the Aedes aegypti and Aedes albopictus mos- protein (C), the membrane protein (M), and the envelope quitoes. The mosquito becomes infected when it feeds on blood protein (E). The viral genome is composed of an approximately Viral Disease and Vaccine Translational Research Unit, and Vaccine Centre, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai 200031, China. Correspondence: X Jin, M.D., Ph.D., Professor, Principal Investigator, Chief, Viral Disease and Vaccine Translational Research Unit, B507 Life Science Research Building, 320 Yueyang Road, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai 200031, China. E-mail: xjin@ips.ac.cn Received: 5 April 2015; Revised 15 June 2015; Accepted 14 July 2015 Guiding dengue vaccine development H Liang et al 37 a Structural Non-Structural 5'UTR C prIM E NS1 NS2ANS3 NS4B NS5 3'UTR NS2B NS4A Protease RNA-dependent RNA polymetase NTPase Methyltransfetase RTPase Helicase Host cell signalase cleavage site Furin cleavage site Viral NS2B/NS3 protease cleavage site Unidentified protease cleavege site b DENV-1 DENV-3 DENV-2 DENV-4 JEV YFV 0.1 Figure 1 Structure of the flavivirus genome and genetic distance of selected flaviviruses.(a). Genomic structure and polyprotein processing of flaviviruses. The positive-sense RNA genome forms a single open-reading frame that is translated into a polyprotein precursor containing three structural proteins (blue) and seven NS proteins (yellow) flanked by the 59 and 39 UTRs. Cleavage sites for the host-cell signalase and furin, and the viral NS2B/NS3 protease as well as an unidentified protease are indicated by arrows. The functions of the NS3 and NS5 proteins that are required for RNA replication and polyprotein processing are also shown. (b). Phylogenetic analysis of selected flaviviruses. A neighbor-joining tree was compiled with complete genome sequences of DENV, JEV, and YFV available in the GenBank database using a Kimura two-parameter model. Sequence alignment and phylogenetic analysis were performed with MEGA 6 software(Oxford, UK). Virus sequences included are DENV-1 Hawaii, DENV-2 16681, DENV-3 H87, DENV-4 H241, JEV JaOArS982, and YFV ASIBI. 11,000-nucleotide single-stranded, positive-sense RNA assemble at the intracellular membranes of infected cells.19 (ssRNA). This ssRNA encodes the three structural proteins The viral C protein and ssRNA form a nucleocapsid structure, and seven non-structural (NS) proteins in a single open-read- probably in association with the membranes of the endoplas- ing frame that is flanked by untranslated regions (UTRs) at mic reticulum (ER). Then, the prM and E proteins are trans- either end, forming the gene order 59UTR-C-prM-E-NS1- ferred into the lumen of the ER to form a heterotrimeric prM/E NS2A-NS2B-NS3-NS4A-NS4B-NS5-39UTR.8,9 complex that surrounds the nucleocapsid. The prM protein is DENV infection is initiated by viral attachment to the recep- further cleaved into the pr and M proteins by the furin protease tors on target cells, followed principally by clathrin-mediated during a pH-dependent virion maturation process. endocytosis or other less predominant modes of entry. The The mechanism by which the immune response confers pro- virus E protein dimers undergo a conformational change with tection against the virus is likely to involve the targeting of a the gradual acidification of the endosome to expose the fusion specific structural component or a particular step of viral rep- loop, leading to fusion between the viral and endosomal mem- lication. Elucidating how successful vaccines have worked in branes.10,11 Then, the uncoated viral ssRNA is released into the the past will provide a useful guide for vaccine research and cytoplasm and translated into a polyprotein that is subse- development in the future. The YFV-17D vaccine for yellow quently cleaved by virus-encoded or host-cell proteases into fever is an ideal example of a successful vaccine that can serve as three structural proteins (C, prM, and E) and seven NS proteins a gold-standard to determine the immune correlates of vac- (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5).12 Viral geno- cine-induced protection. mic RNA synthesis is based on a double-stranded RNA (dsRNA) template in the viral replication complex, which is YELLOW FEVER AND YELLOW FEVER VACCINES located within virus-induced membrane structures originating YFV is the prototype member of the flavivirus genus and is the from the trans-Golgi network or the intermediate compart- source of the genus name. YFV rampantly attacked the world ment.13 Most viral NS proteins and the core protein are population (especially in Africa, America, and Europe) for over involved in the replication process.14–18 Flavivirus virions 200 years until the French neurotropic vaccine (FNV) and Cellular & Molecular Immunology Guiding dengue vaccine development H Liang et al 38 Table 1 Comparison between FNV and yellow fever-17D (YF-17D) vaccinea FNV YF-17D vaccine Origin French viscerotropic virus strain Asibi strain Attenuation ,128 times in mouse brain ,17 times in mouse embryo tissue ,58 times in chick embryo tissue ,128 times in chick embryo tissue without nerve tissue Inoculation Scarification Subcutaneous inoculation Side effects Post-vaccination encephalitis YEL-AVD and YEL-ANDb Efficacy ,90%c .90% Amino acid DI & DII 52G, 54V, 56A, 84K, 142R, 153K, 170A, 173T, 52R, 54A, 56V, 84E, 142Q, 153N, 170V, 173I, 200T, 249N differences 200K, 249D DIII 305S, 325P, 380T 305F, 325S, 380R a Adapted from references24,122–125. b YEL-AVD, YF vaccine-associated viscerotropic disease; YEL-AND, YF vaccine-associated neurotropic disease. c Estimated based on seroconversion rates. yellow fever 17D vaccine (YF-17D) were developed in the unwanted adverse events may occur. In contrast, when viremia 1930s. Although highly efficacious, the use of FNV was stopped is absent the viral replication may be too limited to produce in 1981 due to its association with an increased risk of post- sufficient antigens to stimulate the magnitude of immune res- vaccination encephalitis (Table 1).20 The YF-17D vaccine was ponse required for protection. Thus, an appropriate level of developed by successive passages of the Asibi strain of YFV in viremia is crucial to activate multiple types of immune res- mouse embryo tissue culture, chicken embryo tissue culture, ponses after immunization.
Load more

Recommended publications
  • Flavivirus: from Structure to Therapeutics Development
    life Review Flavivirus: From Structure to Therapeutics Development Rong Zhao 1,2,†, Meiyue Wang 1,2,†, Jing Cao 1,2, Jing Shen 1,2, Xin Zhou 3, Deping Wang 1,2,* and Jimin Cao 1,2,* 1 Key Laboratory of Cellular Physiology, Ministry of Education, Shanxi Medical University, Taiyuan 030001, China; zhaorong@b.sxmu.edu.cn (R.Z.); wangmeiyue0808@b.sxmu.edu.cn (M.W.); caojing@b.sxmu.edu.cn (J.C.); shenjing@sxmu.edu.cn (J.S.) 2 Department of Physiology, Shanxi Medical University, Taiyuan 030001, China 3 Department of Medical Imaging, Shanxi Medical University, Taiyuan 030001, China; xzhou@sxmu.edu.cn * Correspondence: wangdeping@sxmu.edu.cn (D.W.); caojimin@sxmu.edu.cn (J.C.) † These authors contributed equally to this work. Abstract: Flaviviruses are still a hidden threat to global human safety, as we are reminded by recent reports of dengue virus infections in Singapore and African-lineage-like Zika virus infections in Brazil. Therapeutic drugs or vaccines for flavivirus infections are in urgent need but are not well developed. The Flaviviridae family comprises a large group of enveloped viruses with a single-strand RNA genome of positive polarity. The genome of flavivirus encodes ten proteins, and each of them plays a different and important role in viral infection. In this review, we briefly summarized the major information of flavivirus and further introduced some strategies for the design and development of vaccines and anti-flavivirus compound drugs based on the structure of the viral proteins. There is no doubt that in the past few years, studies of antiviral drugs have achieved solid progress based on better understanding of the flavivirus biology.
    [Show full text]
  • Dengue Fever and Dengue Hemorrhagic Fever (Dhf)
    DENGUE FEVER AND DENGUE HEMORRHAGIC FEVER (DHF) What are DENGUE and DHF? Dengue and DHF are viral diseases transmitted by mosquitoes in tropical and subtropical regions of the world. Cases of dengue and DHF are confirmed every year in travelers returning to the United States after visits to regions such as the South Pacific, Asia, the Caribbean, the Americas and Africa. How is dengue fever spread? Dengue virus is transmitted to people by the bite of an infected mosquito. Dengue cannot be spread directly from person to person. What are the symptoms of dengue fever? The most common symptoms of dengue are high fever for 2–7 days, severe headache, backache, joint pains, nausea and vomiting, eye pain and rash. The rash is frequently not visible in dark-skinned people. Young children typically have a milder illness than older children and adults. Most patients report a non-specific flu-like illness. Many patients infected with dengue will not show any symptoms. DHF is a more severe form of dengue. Initial symptoms are the same as dengue but are followed by bleeding problems such as easy bruising, skin hemorrhages, bleeding from the nose or gums, and possible bleeding of the internal organs. DHF is very rare. How soon after exposure do symptoms appear? Symptoms of dengue can occur from 3-14 days, commonly 4-7 days, after the bite of an infected mosquito. What is the treatment for dengue fever? There is no specific treatment for dengue. Treatment usually involves treating symptoms such as managing fever, general aches and pains. Persons who have traveled to a tropical or sub-tropical region should consult their physician if they develop symptoms.
    [Show full text]
  • Takeda Vaccines Innovation for Global Impact
    TAKEDA VACCINES INNOVATION FOR GLOBAL IMPACT CHOO BENG GOH, MD Regional Lead for Medical Affairs Asia, Global Vaccine Business Unit OUR MISSION Develop and deliver innovative vaccines that tackle the toughest problems in public health and improve the lives of people around the world 2 WE HAVE BUILT A GLOBAL VACCINE BUSINESS UPON A STRONG FOUNDATION IN JAPAN Global pivotal Phase 3 PARTNERSHIPS clinical trial of dengue ACQUISITIONS Polio vaccine vaccine candidate initiated: candidate Japan vaccine business Global vaccine business Dengue vaccine 20,100 participants in 8 Bill & Melinda Gates Foundation established established candidate countries in 2 regions Norovirus vaccine Zika vaccine candidate 1946 2012 candidate 2016 U.S. Government‐ BARDA 1947 2010 2014 2018 1st Takeda Multiple vaccine products Partnered with Japan Phase 3 clinical trial results of manufactured vaccine manufactured internally government to develop and dengue vaccine candidate is and marketed in Japan supply pandemic influenza expected in H2 FY18 vaccines for people in Japan 3 THE VACCINE MARKET IS AN ATTRACTIVE PLACE FOR INVESTMENT Vaccine sales growth projected at 7.1% between Durability in sales with limited impact 2017 and 2024, reaching $44.6 billions in 20241 of patent expiry Blockbuster potential in newly launched vaccines Threat of emerging and existing infectious diseases with epidemic potential 1 Evaluate Pharma report 2018 4 OUR STRATEGY Develop vaccines with global BUILD A GLOBAL TACKLE Target the greatest opportunity relevance and business potential PIPELINE
    [Show full text]
  • Efficacy of Vaccines in Animal Models of Ebolavirus Disease
    Supplemental Table 1. Efficacy of vaccines in animal models of Ebolavirus disease. Vaccines Immunization Schedule Mouse Model Guinea Pig Model NHP Model Virus Vectors HPIV3 Immunogens Guinea Pigs: Complete protection Complete protection HPIV3 ∆HN-F/ EBOV GP IN 4 x 106 PFU of HPIV3 with HPIV3 ∆HN-F/EBOV with 2 doses of [1] ∆HN-F/EBOV GP or GP, HPIV3/EBOV GP, or HPIV3/EBOV GP [3] EBOV GP [1-3] HPIV3/EBOV GP [1] HPIV3/EBOV NP [1, 2] No advantage to EBOV NP [2] IN 105.3 PFU of HPIV/EBOV Strong humoral response bivalent vaccines EBOV GP + NP [3] GP or NP [2] EBOV GP +GM-CSF [3] HPIV3- NHPs: 6 IN plus IT 4 x 10 TCID50 of HPIV3/EBOV GP, HPIV3/EBOV GP+GM-CSF, HPIV3/EBOVGP NP or 2 x 7 10 TCID50 of HPIV3/EBOV GP for 1–2 doses [3] RABV ∆GP/EBOV GP Mice: IM 5 x 105 FFU Complete protection with (Live attenuated) [4] either vector RABV/EBOV GP fused to EBOV GP incorporation into GCD of RABV virions not dependent on (inactivated) [4] RABV GCD Human Ad5 Immunogens Mice: With induced preexisting Ad5 With systemically CMVEBOV GP [5-9] IN, PO, IM 1 x 1010 [6] to 5 immunity, complete induced preexisting Ad5 CAGoptEBOV GP [8, 9] x 1010 [5] particles of protection with only IN immunity, complete Ad5/CMVEBOV GP Ad5/CMVEBOV GP [5] protection with IN IP 1 x 108 PFU With no Ad5 immunity: Ad5/CMVEBOV GP [8] Ad5/CMVEBOV GP[7] complete protection With mucosally induced IM 1 x 104–1 x 107 IFU of regardless of route [5-7, 9] preexisting Ad5 Ad5/CMVEBOV GP or 1 x Mucosal immunization Ad5- immunity, 83% 104–1 x 106 IFU of EBOV GP increased cellular
    [Show full text]
  • Dengue and Yellow Fever
    GBL42 11/27/03 4:02 PM Page 262 CHAPTER 42 Dengue and Yellow Fever Dengue, 262 Yellow fever, 265 Further reading, 266 While the most important viral haemorrhagic tor (Aedes aegypti) as well as reinfestation of this fevers numerically (dengue and yellow fever) are insect into Central and South America (it was transmitted exclusively by arthropods, other largely eradicated in the 1960s). Other factors arboviral haemorrhagic fevers (Crimean– include intercontinental transport of car tyres Congo and Rift Valley fevers) can also be trans- containing Aedes albopictus eggs, overcrowding mitted directly by body fluids. A third group of of refugee and urban populations and increasing haemorrhagic fever viruses (Lassa, Ebola, Mar- human travel. In hyperendemic areas of Asia, burg) are only transmitted directly, and are not disease is seen mainly in children. transmitted by arthropods at all. The directly Aedes mosquitoes are ‘peri-domestic’: they transmissible viral haemorrhagic fevers are dis- breed in collections of fresh water around the cussed in Chapter 41. house (e.g. water storage jars).They feed on hu- mans (anthrophilic), mainly by day, and feed re- peatedly on different hosts (enhancing their role Dengue as vectors). Dengue virus is numerically the most important Clinical features arbovirus infecting humans, with an estimated Dengue virus may cause a non-specific febrile 100 million cases per year and 2.5 billion people illness or asymptomatic infection, especially in at risk.There are four serotypes of dengue virus, young children. However, there are two main transmitted by Aedes mosquitoes, and it is un- clinical dengue syndromes: dengue fever (DF) usual among arboviruses in that humans are the and dengue haemorrhagic fever (DHF).
    [Show full text]
  • First Detection of the West Nile Virus Koutango Lineage in Sandflies In
    pathogens Article First Detection of the West Nile Virus Koutango Lineage in Sandflies in Niger Gamou Fall 1,* , Diawo Diallo 2 , Hadiza Soumaila 3,4, El Hadji Ndiaye 2 , Adamou Lagare 5, Bacary Djilocalisse Sadio 1, Marie Henriette Dior Ndione 1, Michael Wiley 6,7 , Moussa Dia 1, Mamadou Diop 8, Arame Ba 1, Fati Sidikou 5, Bienvenu Baruani Ngoy 9, Oumar Faye 1, Jean Testa 5, Cheikh Loucoubar 8 , Amadou Alpha Sall 1, Mawlouth Diallo 2 and Ousmane Faye 1 1 Pole of Virology, WHO Collaborating Center For Arbovirus and Haemorrhagic Fever Virus, Institut Pasteur, Dakar BP 220, Senegal; Bacary.SADIO@pasteur.sn (B.D.S.); Marie.NDIONE@pasteur.sn (M.H.D.N.); Moussa.DIA@pasteur.sn (M.D.); Arame.ba@pasteur.sn (A.B.); Oumar.FAYE@pasteur.sn (O.F.); Amadou.SALL@pasteur.sn (A.A.S.); Ousmane.FAYE@pasteur.sn (O.F.) 2 Citation: Fall, G.; Diallo, D.; Pole of Zoology, Medical Entomology Unit, Institut Pasteur, Dakar BP 220, Senegal; Soumaila, H.; Ndiaye, E.H.; Lagare, Diawo.DIALLO@pasteur.sn (D.D.); elhadji.ndiaye@pasteur.sn (E.H.N.); mawlouth.diallo@pasteur.sn (M.D.) 3 A.; Sadio, B.D.; Ndione, M.H.D.; Programme National de Lutte contre le Paludisme, Ministère de la Santé Publique du Niger, Niamey BP 623, Niger; hadiza_soumaila@pmivectorlink.com Wiley, M.; Dia, M.; Diop, M.; et al. 4 PMI Vector Link Project, Niamey BP 11051, Niger First Detection of the West Nile Virus 5 Centre de Recherche Médicale et Sanitaire, Niamey BP 10887, Niger; lagare@cermes.org (A.L.); Koutango Lineage in Sandflies in fati@cermes.org (F.S.); jean.testa@unice.fr (J.T.) Niger.
    [Show full text]
  • Florida Arbovirus Surveillance Week 13: March 28-April 3, 2021
    Florida Arbovirus Surveillance Week 13: March 28-April 3, 2021 Arbovirus surveillance in Florida includes endemic mosquito-borne viruses such as West Nile virus (WNV), Eastern equine encephalitis virus (EEEV), and St. Louis encephalitis virus (SLEV), as well as exotic viruses such as dengue virus (DENV), chikungunya virus (CHIKV), Zika virus (ZIKV), and California encephalitis group viruses (CEV). Malaria, a parasitic mosquito-borne disease is also included. During the period of March 28- April 3, 2021, the following arboviral activity was recorded in Florida. WNV activity: No human cases of WNV infection were reported this week. No horses with WNV infection were reported this week. No sentinel chickens tested positive for antibodies to WNV this week. In 2021, positive samples from two sentinel chickens has been reported from two counties. SLEV activity: No human cases of SLEV infection were reported this week. No sentinel chickens tested positive for antibodies to SLEV this week. In 2021, no positive samples have been reported. EEEV activity: No human cases of EEEV infection were reported this week. No horses with EEEV infection were reported this week. No sentinel chickens tested positive for antibodies to EEEV this week. In 2021, positive samples from one horse and 14 sentinel chickens have been reported from four counties. International Travel-Associated Dengue Fever Cases: No cases of dengue fever were reported this week in persons that had international travel. In 2021, one travel-associated dengue fever case has been reported. Dengue Fever Cases Acquired in Florida: No cases of locally acquired dengue fever were reported this week. In 2021, no cases of locally acquired dengue fever have been reported.
    [Show full text]
  • HPV Vaccine Update
    Dengue modeling Andrea Vicari Comprehensive Family Immunization Unit Family, Gender and Life Course Department Outline • Framing modeling within policy cycle • Purposes of infectious disease modeling • Overview of dengue modeling • Final considerations Five stages of a policy cycle Agenda setting • Problem recognition Policy formulation • Proposal of solution Decision-making • Choice of solution Policy implementation • Putting solution into effect Policy evaluation • Monitoring results Howlett & Ramesh, Studying public policy: Policy cycles and policy subsystems, 1995 Identify the decision situation and A decision- understand objectives analysis process Identify alternatives flowchart Decompose and model the problem: 1. Model of problem structure 2. Model of uncertainty 3. Model of preferences Choose best alternatives Sensitivity analysis Is further YES analysis necessary? NO Implement chosen alternative Clemen and Reilly, Making hard decisions, 2002. Main purposes of infectious disease modeling • To understand fundamental driving forces of disease ecology and epidemiology • To measure epidemiological parameters that cannot be directly measured with field or laboratory data • To make predictions of future disease incidence under specified conditions • To forecast impact of different prevention/control measures and their combination Adapted from: WHO-VMI Dengue Vaccine Modeling Group, PLoS Negl Trop Dis 2012, 6:e1450 Classical Ross-Macdonald model for malaria transmission (1) Classical Ross-Macdonald model for malaria transmission (2) m
    [Show full text]
  • Dengue Vaccine: Global Development Update
    REVIEW ARTICLE Asian Pacific Journal of Allergy and Immunology Dengue vaccine: Global development update Eakachai Prompetchara,1,2,3 Chutitorn Ketloy,3,4 Stephen J. Thomas,5 Kiat Ruxrungtham4,6 Abstract The first licensed dengue vaccine, CYD-TDV (Dengvaxia®), has received regulatory approval in a number of countries. However, this vaccine has some limitations. Its efficacy against DENV2 was consistently lower than other serotypes. Protective efficacy also depended on prior dengue sero-status of the vaccinees. Lower efficacy was observed in children with < 9 years old and dengue-naïve individuals. More importantly, risk of hospitalization and severe dengue was in- creased in the youngest vaccine recipients (2-5 years) compared to controls. Thus, the quest of a better vaccine candi- date continues. There are two live-attenuated vaccine candidates currently testing in phase III trial including DENVax, developed by US CDC and Inviragen (now licensed to Takeda) and TV003/TV005, constructed by US NIAID. In addi- tion, there are several phase I–II as well as preclinical phase studies evaluating vaccines for safety and immunogenicity, this include other live-attenuated platform/strategy, purified-inactivated viruses formulated with adjuvants, DNA vac- cine, subunit vaccine, viral vector and also heterologous prime/boost strategies. The major difficulties of dengue vaccine development are included the lack of the best animal model, various immune status of individual especially in endemic areas and clear cut off of protective immunity. Several research and development efforts are ongoing to find a better effec- tive and accessible dengue vaccine for people needed. Key words: Dengue vaccine, Live-attenuated virus, Inactivated virus, DNA vaccine, Subunit vaccine, Heterologous prime- boost From: is the result of worldwide transportation and travel, increas- 1 Department of Biochemistry and Microbiology, ing urbanization, as well as climate change which support Faculty of Pharmaceutical Sciences, Chulalongkorn University, 3 Bangkok, Thailand the spreading of Aedes mosquitoes.
    [Show full text]
  • Combatting Malaria, Dengue and Zika Using Nuclear Technology by Nicole Jawerth and Elodie Broussard
    Infectious Diseases Combatting malaria, dengue and Zika using nuclear technology By Nicole Jawerth and Elodie Broussard A male Aedes species mosquito. iseases such as malaria, dengue and transcription–polymerase chain reaction (Photo: IAEA) Zika, spread by various mosquito (RT–PCR) (see page 8). Experts across the Dspecies, are wreaking havoc on millions of world have been trained and equipped by lives worldwide. To combat these harmful the IAEA to use this technique for detecting, and often life-threatening diseases, experts tracking and studying pathogens such as in many countries are turning to nuclear and viruses. The diagnostic results help health nuclear-derived techniques for both disease care professionals to provide treatment and detection and insect control. enable experts to track the viruses and take action to control their spread. Dengue and Zika When a new outbreak of disease struck in The dengue virus and Zika virus are mainly 2015 and 2016, physicians weren’t sure of spread by Aedes species mosquitoes, which its cause, but RT–PCR helped to determine are most common in tropical regions. In most that the outbreak was the Zika virus and not cases, the dengue virus causes debilitating another virus such as dengue. RT–PCR was flu-like symptoms, but all four strains of the used to detect the virus in infected people virus also have the potential to cause severe, throughout the epidemic, which was declared life-threatening diseases. In the case of the Zika a public health emergency of international virus, many infected people are asymptomatic concern by the World Health Organization or only have mild symptoms; however, the virus (WHO) in January 2016.
    [Show full text]
  • Dengue Fever (Breakbone Fever, Dengue Hemorrhagic Fever)
    Division of Disease Control What Do I Need to Know? Dengue Fever (breakbone fever, dengue hemorrhagic fever) What is Dengue Fever? Dengue fever is a serious form of mosquito-borne disease caused one of four closely related viruses called Flaviviruses. They are named DENV 1, DENV 2, DENV 3, or DENV 4. The disease is found in most tropical and subtropical areas (including some islands in the Caribbean, Mexico, most countries of South and Central America, the Pacific, Asia, parts of tropical Africa and Australia). Almost all cases reported in the continental United States are in travelers who have recently returned from countries where the disease circulates. Dengue is endemic to the U.S. territories of Puerto Rico, the Virgin Islands, and Guam and in recent years non-travel related cases have been found in Texas, Florida, and Hawaii. Who is at risk for Dengue Fever? Dengue fever may occur in people of all ages who are exposed to infected mosquitoes. The disease occurs in areas where the mosquitos that carry dengue circulate, usually during the rainy seasons when mosquito populations are at high numbers. What are the symptoms of Dengue Fever? Dengue fever is characterized by the rapid development of fever that may last from two to seven days, intense headache, joint and muscle pain and a rash. The rash develops on the feet or legs three to four days after the beginning of the fever. Some people with dengue develop dengue hemorrhagic fever (DHF). Symptoms of DHF are characteristic of internal bleeding and include: severe abdominal pain, red patches on skin, bleeding from nose or gums, black stools, vomiting blood, drowsiness, cold and clammy skin and difficulty breathing.
    [Show full text]
  • COVID-19 Vaccine-Mediated Enhanced Disease (VMED)
    COVID-19 Vaccine-Mediated Enhanced Disease and Vaccine Effectiveness in the Vaccine Safety Datalink VSD Study #1341 PROTOCOL VERSION: 1.2 DATE: 27 April 2021 KEY STUDY STAFF Marshfield Clinic Research Institute (MCRI) Principal Investigator Edward Belongia, MD Co-Investigators Thomas Boyce, MD, MPH James Donahue, DVM, PhD Dave McClure, PhD Biostatistician Burney Kieke Jr., MS Project Managers Kayla Hanson, MPH Hannah Berger, MPH Data Manager Erica Scotty, MS Project Administrator Bobbi Bradley, MPH, MBA Vaccine Safety Datalink Collaborating Site Investigators and Project Managers Denver Health Joshua Williams, MD Jonathan Block, MEd, PMP Harvard Pilgrim Katherine Yih, PhD, MD Jessica LeBlanc, MPH HealthPartners Malini DeSilva, MD, MPH Leslie Kuckler, MPH Kaiser Permanente Matt Daley, MD Colorado Jo Ann Shoup, PhD Kaiser Permanente Nicky Klein, MD, PhD Northern California Kristin Goddard, MPH (AIM 2) Kaiser Permanente Stephanie Irving, MHS Northwest Tia Kauffman, MPH Kaiser Permanente Bruno Lewin, MD Southern California Cheryl Carlson, MPH (AIM 2) Denison Ryan, MPH Kaiser Permanente Lisa Jackson, MD, MPH Washington Erika Kiniry, MPH Centers for Disease Control and Prevention (CDC) Investigators Immunization Safety Jonathan Duffy, MD, MPH Office Michael McNeil, MD, MPH COVID-19 VE Team TBN Page ii PROTOCOL CHANGE HISTORY Version/Date Summary of Change 1.0/26 March 2021 Original protocol 1.1/21 April 2021 Minor revisions to eligibility criteria, exposure classification, and covariates 1.2/27 April 2021 Minor revisions to data lag and Aim 2 endpoints PROTOCOL SYNOPSIS Title: COVID-19 VMED and Vaccine Effectiveness in the VSD Short name: COVID-19 VMED/VE Study Rationale Vaccine-mediated enhanced disease (VMED) can result from immune complex formation and Th2 biased cellular immune response when vaccinated individuals become infected with the target pathogen.
    [Show full text]